z-logo
Premium
Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study
Author(s) -
Yoshida Masaki,
Takeda Masayuki,
Gotoh Momokazu,
Yokoyama Osamu,
Kakizaki Hidehiro,
Takahashi Satoru,
Masumori Naoya,
Nagai Shinji,
Minemura Kazuyoshi
Publication year - 2021
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.24732
Subject(s) - medicine , placebo , overactive bladder , subgroup analysis , post hoc analysis , blood pressure , urination , urology , lower urinary tract symptoms , adverse effect , randomized controlled trial , anesthesia , urinary system , confidence interval , prostate , alternative medicine , pathology , cancer
Aims To examine the safety and efficacy of vibegron, a new β3‐adrenoceptor agonist, in patients aged ≥65 years, with a focus on the effects on cardiovascular system and overactive bladder (OAB) symptoms. Methods A post‐hoc subgroup analysis was performed of a randomized, placebo‐controlled, double‐blind comparative phase 3 study of vibegron, including those assigned to receive either vibegron 50 mg (V50), vibegron 100 mg (V100), or placebo for 12 weeks. Subjects were stratified into two subgroups based on age: a <65‐year subgroup and a ≥65‐year subgroup. Safety (changes in systolic and diastolic blood pressure, pulse rate, and residual urine volume) and efficacy (changes in the numbers of micturitions, urgency episodes, urgency urinary incontinence [UUI] episodes, and the voided volume/micturition) were assessed in the subgroups treated with vibegron vs. placebo. Results There were no significant differences in the cardiovascular outcomes (blood pressure and pulse rate), nor in the changes in residual urine volume, between the V50/100 and placebo groups in the <65‐year or ≥65‐year subgroup after 12‐week treatment. Adverse events were slightly increased in the ≥65‐year subgroup. In the efficacy analysis, V50/100 demonstrated similar efficacy in the <65‐year and ≥65‐year subgroups; an increasing trend in the voided volume/micturition was observed in subjects aged ≥65 years compared to subjects aged <65 years. Conclusions Vibegron was suggested to be similarly effective in patients ≥65 and <65 years and to have minimal influence on cardiovascular parameters.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here